Skip to Main Content

INFORMATION FOR

    Karthik Chetlapalli

    DownloadHi-Res Photo

    About

    Biography

    Karthik is currently a Yale medical student, having had diverse experiences across medicine and biotech. He began his career at the University of Southern California in Los Angeles. While an undergrad, he worked as a synaptic electrophysiology research assistant, an ambulance EMT, and a vice president for a student-run veteran’s rehabilitation organization. Later as a business development intern for Neurocrine Biosciences, he screened academic institutes and upcoming startups for novel neuropsychiatric therapeutics.

    During his Master’s, Karthik explored the prospect of new stem-cell-based methods for use in antifibrotics and next-generation (CAR) cell therapy. While he worked as a lab assistant for kidney organoid research at USC, Karthik started and led his non-profit SROA to tackle stem cell treatment fraud. More recently, Karthik worked at City of Hope as a clinical genetics assistant, supporting genetic counseling and precision medicine for patients facing cancer. As a current medical student, Karthik is interested in clinical trial equity, cancer outcomes, immuno-oncology therapeutics, and the power of venture capital in advancing medicine.

    Karthik earned an M.S. in Stem Cell Biology and a B.S. in Neuroscience with a minor in Health Care Studies from the University of Southern California.

    Last Updated on March 26, 2024.

    Education & Training

    MS
    University of Southern California, Stem Cell Biology
    BS
    University of Southern California, Neuroscience (2021)

    Research

    Research at a Glance

    Yale Co-Authors

    Frequent collaborators of Karthik Chetlapalli's published research.

    Publications

    2026

    • Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis
      Chetlapalli K, Ito S, Ng DQ, Sra MS, Wang D, Krumholz H, Krishnamurti L, Pandya A, Goshua G. Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis. Blood Journal 2026, blood.2025032290. DOI: 10.1182/blood.2025032290.
      Peer-Reviewed Original Research
      This study investigates the cost-effectiveness of haploidentical stem cell transplantation, gene therapy, and standard care for sickle cell disease, showing transplantation offers the best value globally.

    2024